Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR1 wild-type |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR1 wild-type | breast cancer | resistant | Ponatinib | Preclinical | Actionable | In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366). | 22238366 | |
| FGFR1 wild-type | lung cancer | decreased response | Fexagratinib | Preclinical | Actionable | In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to Fexagratinib (AZD4547) induced growth inhibition in culture and in xenograft models (PMID: 23082000). | 23082000 |